Literature DB >> 11158889

Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas.

M Castillo1, J K Smith, L Kwock, K Wilber.   

Abstract

BACKGROUND AND
PURPOSE: Preliminary data indicate that apparent diffusion coefficient (ADC) values may be useful in identifying and grading primary cerebral tumors. We tested the hypothesis that ADC values can be used to differentiate tumor, edema, and normal brain tissue.
METHODS: Fifteen patients with high-grade cerebral astrocytomas underwent conventional MR imaging, diffusion-weighted MR imaging, and proton MR spectroscopy. We defined tumor as an area containing the highest choline/creatine and choline/N-actetyl aspartate ratios, contrast enhancement, and abnormal T2 signal intensity. Edema was defined as tissue with normal proton MR spectra, no enhancement, and high T2 signal intensity. Normal brain was assumed if tissue had normal proton MR spectra, no enhancement, and normal T2 signal intensity in the hemispheres ipsilateral or contralateral to tumor. ADC maps were calculated and regions of interest were manually placed over areas of tumor, edema, and normal tissue. Comparisons were made by analysis of variance. For post hoc testing, the Tukey method was used to correct for the effect of multiple comparisons, and significance was accepted if P was less than .05.
RESULTS: When ADC values were analyzed as a group, significant differences were found between tumor (131 + 45) and normal brain tissue (ipsilateral to tumor, 92 + 22; contralateral to tumor, 78 + 5) but not between tumor and adjacent edema (129 + 45). A plot of individual data points showed considerable overlapping among the three types of tissue sampled.
CONCLUSION: As a group, ADC values helped to distinguish high-grade glioma from normal tissue but could not be used to separate high-grade glioma from surrounding edema. Individually, ADC values overlapped considerably and were not useful in our patients. The utility of ADC values (as obtained in this relatively small study) is questionable in patients with high-grade cerebral astrocytomas.

Entities:  

Mesh:

Year:  2001        PMID: 11158889      PMCID: PMC7975568     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  6 in total

1.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

2.  Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma.

Authors:  R K Gupta; U Sinha; T F Cloughesy; J R Alger
Journal:  Magn Reson Med       Date:  1999-01       Impact factor: 4.668

3.  MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences.

Authors:  R D Tien; G J Felsberg; H Friedman; M Brown; J MacFall
Journal:  AJR Am J Roentgenol       Date:  1994-03       Impact factor: 3.959

4.  Quantitative diffusion MR imaging of cerebral tumor and edema.

Authors:  M Eis; T Els; M Hoehn-Berlage; K A Hossmann
Journal:  Acta Neurochir Suppl (Wien)       Date:  1994

5.  High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat.

Authors:  M Eis; T Els; M Hoehn-Berlage
Journal:  Magn Reson Med       Date:  1995-12       Impact factor: 4.668

6.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.

Authors:  T L Chenevert; P E McKeever; B D Ross
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

  6 in total
  73 in total

1.  Neuroimaging and cartography: mapping brain tumors.

Authors:  M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

Review 2.  Diffusion tensor imaging of the brain: review of clinical applications.

Authors:  P C Sundgren; Q Dong; D Gómez-Hassan; S K Mukherji; P Maly; R Welsh
Journal:  Neuroradiology       Date:  2004-04-21       Impact factor: 2.804

Review 3.  Methodology of diffusion-weighted, diffusion tensor and magnetisation transfer imaging.

Authors:  S J Price; D J Tozer; J H Gillard
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

5.  Diffusion MRI findings in phenylketonuria.

Authors:  R N Sener
Journal:  Eur Radiol       Date:  2003-02-18       Impact factor: 5.315

6.  High b-value diffusion (b = 3000 s/mm2) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm2.

Authors:  H S Seo; K-H Chang; D G Na; B J Kwon; D H Lee
Journal:  AJNR Am J Neuroradiol       Date:  2007-12-07       Impact factor: 3.825

7.  Neuroradiological assessment of newly diagnosed glioblastoma.

Authors:  Srini Mukundan; Chad Holder; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

Review 8.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

9.  MR imaging of orbital inflammatory syndrome, orbital cellulitis, and orbital lymphoid lesions: the role of diffusion-weighted imaging.

Authors:  R Kapur; A R Sepahdari; M F Mafee; A M Putterman; V Aakalu; L J A Wendel; P Setabutr
Journal:  AJNR Am J Neuroradiol       Date:  2008-10-08       Impact factor: 3.825

10.  Diffusion imaging for therapy response assessment of brain tumor.

Authors:  Thomas L Chenevert; Brian D Ross
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.